PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Markku Laakso Selected Research
Type 2 Diabetes Mellitus (MODY)
03/2008
Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome: The Finnish Diabetes Prevention Study.
04/2007
Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
07/2006
Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
03/2005
The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
05/2004
The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.
01/2004
Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus.
07/2003
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
06/2002
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Articles by Research Topic
Disease
8
Type 2 Diabetes Mellitus (MODY)
03/2008 - 06/2002
7
Coronary Disease (Coronary Heart Disease)
03/2007 - 03/2002
4
Syndrome
03/2008 - 12/2004
4
Hypertrophic Cardiomyopathy (Asymmetric Septal Hypertrophy)
05/2007 - 01/2003
3
Insulin Resistance
02/2008 - 03/2004
3
Pre-Eclampsia (Preeclampsia)
09/2006 - 10/2002
3
Obesity
07/2006 - 07/2003
3
Alzheimer Disease (Alzheimer's Disease)
01/2006 - 01/2002
3
Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
12/2004 - 12/2003
2
Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
09/2005 - 09/2004
2
Cardiovascular Diseases (Cardiovascular Disease)
07/2003 - 01/2003
1
Heart Failure
04/2008
1
Hyperglycemia
02/2008
1
Atherosclerosis (Atheroma)
10/2007
1
Thinness
06/2007
1
Metabolic Diseases (Metabolic Disease)
12/2006
1
Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
03/2006
1
Myocardial Infarction
02/2006
1
Hyperinsulinism (Hyperinsulinemia)
01/2006
1
Chest Pain (Chest Pains)
12/2005
1
Type 1 Diabetes Mellitus (Autoimmune Diabetes)
08/2005
1
Tissue Adhesions
12/2004
1
Multiple Abnormalities
12/2004
1
Hypoglycemia (Reactive Hypoglycemia)
08/2004
1
Weight Gain
07/2004
1
Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial)
04/2004
1
Hypertension (High Blood Pressure)
07/2003
1
Myocardial Ischemia (Ischemic Heart Diseases)
06/2003
1
Familial Hypertrophic Cardiomyopathy (Cardiomyopathy, Familial Hypertrophic)
07/2002
Drug/Important Bio-Agent (IBA)
7
Glucose (Dextrose)
FDA Link
Generic
04/2007 - 07/2003
5
Adiponectin
IBA
01/2007 - 12/2004
4
Tropomyosin
IBA
05/2007 - 01/2003
3
Interleukin-6 (Interleukin 6)
IBA
03/2008 - 07/2005
3
Insulin (Novolin)
FDA Link
02/2006 - 07/2003
3
Acarbose
FDA Link
Generic
07/2003 - 06/2002
2
Cytokines
IBA
04/2008 - 12/2004
2
Cholesterol
IBA
06/2007 - 03/2004
2
C-Reactive Protein
IBA
01/2007 - 02/2006
2
Lipase (Acid Lipase)
IBA
09/2006 - 05/2004
2
Ventricular Myosins
IBA
03/2006 - 12/2004
2
PPAR gamma
IBA
01/2006 - 10/2002
1
Diacylglycerol Kinase
IBA
02/2008
1
Peroxisome Proliferator-Activated Receptors (PPAR)
IBA
10/2007
1
GTP-Binding Proteins (G-Protein)
IBA
06/2007
1
PPAR alpha
IBA
04/2007
1
Zinc
IBA
03/2007
1
Interleukin-1 (Interleukin 1)
IBA
01/2007
1
resveratrol
IBA
12/2006
1
Spermine
IBA
10/2006
1
Spermidine
IBA
10/2006
1
Squalene
IBA
07/2006
1
myosin-binding protein C
IBA
03/2006
1
Dihydroxyphenylalanine (Dopa)
IBA
01/2006
1
Autoantibodies
IBA
12/2005
1
oxidized low density lipoprotein
IBA
12/2005
1
Glutamate Decarboxylase (Decarboxylase, Glutamate)
IBA
08/2005
1
Advanced Glycosylation End Products
IBA
04/2005
1
Membrane Glycoproteins (Membrane Glycoprotein)
IBA
09/2004
1
Glucokinase
IBA
08/2004
1
Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)
IBA
07/2004
1
Lamin Type A (Lamin A)
IBA
05/2004
1
Transcription Factors (Transcription Factor)
IBA
04/2004
1
Homocysteine
IBA
01/2004
1
Sarcoglycans (beta Sarcoglycan)
IBA
12/2003
1
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
IBA
07/2003
1
Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
IBA
06/2003
1
Dietary Fats (Ghee)
IBA
03/2003
1
Cardiac Myosins
IBA
07/2002
1
Carrier Proteins (Binding Protein)
IBA
07/2002
1
preproneuropeptide Y
IBA
03/2002
1
Proline (L-Proline)
FDA Link
03/2002
1
Lipids
IBA
03/2002
1
Leucine (L-Leucine)
FDA Link
03/2002
1
Interleukin-1alpha (Interleukin 1 alpha)
IBA
01/2002
Therapy/Procedure
1
Stents
06/2003